标题
A practical review on carfilzomib in multiple myeloma
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 96, Issue 6, Pages 564-577
出版商
Wiley
发表日期
2016-02-20
DOI
10.1111/ejh.12749
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma
- (2016) Xuemei Cai et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
- (2016) A Rosenthal et al. Blood Cancer Journal
- Fatal pulmonary toxicity due to carfilzomib (Kyprolis™)
- (2016) Abdel Rahman Lataifeh et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma
- (2015) Yok-Lam Kwong ANNALS OF HEMATOLOGY
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
- (2015) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
- (2015) Eli Muchtar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2015) Pierre Squifflet et al. Clinical Lymphoma Myeloma & Leukemia
- ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
- (2015) Sophia Danhof et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The use of novel agents in multiple myeloma patients with hepatic impairment
- (2015) Lindsay C Stansfield et al. Future Oncology
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma
- (2015) E. Wilson Grandin et al. JOURNAL OF CARDIAC FAILURE
- Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2015) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Relapsed Multiple Myeloma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
- (2015) S Atrash et al. Blood Cancer Journal
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
- (2015) Fabrizio Accardi et al. Biomed Research International
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
- (2014) Ajai Chari et al. BMC CANCER
- Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
- (2014) Andrzej J. Jakubowiak CANCER TREATMENT REVIEWS
- Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange
- (2014) Matthew R. Sullivan et al. JOURNAL OF CLINICAL APHERESIS
- Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
- (2014) J R Berenson et al. LEUKEMIA
- Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine
- (2014) Rimda Wanchoo et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
- (2013) M. Wang et al. BLOOD
- A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors
- (2013) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
- (2013) A J Jakubowiak et al. LEUKEMIA
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
- (2013) Tzu-Fei Wang et al. LEUKEMIA & LYMPHOMA
- Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
- (2013) L. Vincenz et al. MOLECULAR CANCER THERAPEUTICS
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
- (2013) H. A. F. Stessman et al. MOLECULAR CANCER THERAPEUTICS
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- The role of the proteasome in heart disease
- (2010) Yi-Fan Li et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started